Epitalon
Also called Epithalon, AEDG, Ala-Glu-Asp-Gly.
Epitalon has no FDA-approved product. This page cites 3 sources, and the strongest evidence comes from human trials.
- Status
- No FDA-approved product
- Form
- Injection
- Half-life
- Not modeled
- Strongest evidence
- Human trials
- Cited claims
- 2
- Last updated
- November 6, 2026
What the evidence says
Each claim names the kind of study behind it, what it can't tell you, and where it comes from.
Lab studies
A 2003 laboratory study reported telomerase activity and telomere elongation after adding Epithalon to cultures of human fetal fibroblasts. These were cell-culture measurements.
Limits: No participants received treatment in this experiment. A study in human-derived cells is not a human clinical trial. These measurements do not demonstrate longer human life, improved health, or the safety of repeated systemic exposure.
Human trials
A small controlled study of sublingual AEDG in middle-aged female night workers reported increased urinary melatonin-metabolite excretion and changes in blood-cell clock-gene expression.
Limits: FDA describes 20 treated and 20 placebo participants with low baseline melatonin output. Blinding was unspecified, sleep outcomes were absent, and the studied sublingual formulation does not validate injectable epitalon or a longevity regimen.
Regulatory status
United States
No FDA-approved product was identified. HHS's October 2026 draft, nonbinding 503A policy includes epitalon acetate for intermittent subcutaneous or intramuscular preparations under stated conditions. This is not drug approval or validation of longevity claims. Evidence from epithalamin extract cannot establish efficacy for synthetic epitalon.